Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Narrative) (Details)

v3.21.2
Fair Value Measurements (Narrative) (Details)
$ in Thousands
 1 Months Ended 9 Months Ended
Oct. 06, 2021
USD ($)
Oct. 05, 2021
Mar. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
$ / shares
Dec. 31, 2020
USD ($)
$ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Common stock, value       $ 99 $ 95
Caelum [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Fair value of investment       17,600 $ 17,600
Caelum [Member] | AstraZeneca [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Fair value of investment       $ 56,900  
Percentage of net proceeds expected to receive upon distribution of the option exercise price       42.40%  
Percentage of escrow holdback       10.00%  
Deconsolidation of partner company, escrow distribution period       24 months  
Legal expenses related to deconsolidation       $ 1,100  
Caelum [Member] | Share Price [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investment, measurement input | $ / shares       2.43 2.43
Caelum [Member] | Risk Free Interest Rate [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investment, measurement input       0.0036  
Caelum [Member] | Expected Volatility [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investment, measurement input       0.70  
Caelum [Member] | Discount for Lack of Marketability [Member] | Minimum [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investment, measurement input       0.21  
Caelum [Member] | Discount for Lack of Marketability [Member] | Maximum [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investment, measurement input       0.31  
Journey [Member] | DFD Agreement [Member] | Dr. Reddy's Laboratories, Ltd [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Minimum market capitalization for contingent payment       $ 150,000  
Journey [Member] | DFD Agreement [Member] | Dr. Reddy's Laboratories, Ltd [Member] | Contingent Conditions are Met [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Common stock, value       $ 5,000  
Journey [Member] | DFD Agreement [Member] | Dr. Reddy's Laboratories, Ltd [Member] | Contingent Conditions are not Met [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent payment warrants, agreement terms       Journey or its affiliate executes a definitive agreement for an acquisition event during the period beginning on June 29, 2021 and ending twenty-four (24) months after the regulatory approval of DFD-29, Journey shall pay to DRL: (a) 20% of the value of DFD-29 attributable to the acquisition event, if such acquisition event occurs between closing and NDA approval; or (b) 12% of the value of DFD-29 attributable to the acquisition event, if such acquisition event occurs within 24 months after  
Journey [Member] | 8% Cumulative Convertible Class A Preferred Stock [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Percentage of common stock for which the Preferred A is exchanged     15.00%    
Journey [Member] | 8% Cumulative Convertible Class A Preferred Stock [Member] | Preferred Stock has not been Converted into Journey Common Stock [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Preferred stock offering, aggregate proceeds     $ 25,000    
Journey [Member] | 8% Cumulative Convertible Class A Preferred Stock [Member] | Minimum [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Preferred stock offering, aggregate proceeds     12,500    
Journey [Member] | 8% Cumulative Convertible Class A Preferred Stock [Member] | Maximum [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Preferred stock offering, aggregate proceeds     $ 30,000    
Placement Agent Warrants [Member] | Journey [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Warrants, fair value       $ 500  
Placement Agent Warrants [Member] | Journey [Member] | 8% Cumulative Convertible Class A Preferred Stock [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Percentage of common stock for which the Preferred A is exchanged       5.00%  
Warrant expiration term       5 years  
Warrants exercise price discount percentage       15.00%  
Placement Agent Warrants [Member] | Journey [Member] | 8% Cumulative Convertible Class A Preferred Stock [Member] | Preferred Stock has not been Converted into Journey Common Stock [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Preferred stock offering, aggregate proceeds       $ 25,000  
Contingent Payment Warrant [Member] | Journey [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Warrants, fair value       $ 3,800 $ 0
Subsequent Events [Member] | Caelum [Member] | AstraZeneca [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Deconsolidation of consolidated partner company, upfront payment $ 150,000        
Percentage of escrow holdback   10.00%